Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04581954 | Inflammatory Signal Inhibitors for COVID-19 (MATIS) | PHASE1 | COMPLETED | 185 | — | — | Oct 2, 2020 | Sep 2, 2023 | Nov 18, 2025 | 5 | United Kingdom |
Patients are recruited at a WHO COVID-19 Severity Score of 3 and 4 and the primary endpoint is the comparison of patients whose COVID-19 pneumonia progresses to a severity score ≥ 5 on the modified WHO Ordinal Scale. Specifically, the primary endpoint is met when the following are recorded within 14 days: * Death * Requirement for invasive ventilation * Requirement for non-invasive ventilation including CPAP or high flow nasal oxygen * O2 saturation \< 90% on ≥60% inspired oxygen
| Arm | Type | Description |
|---|---|---|
| Standard of care | ACTIVE_COMPARATOR | - |
| Fostamatinib | ACTIVE_COMPARATOR | - |
| Ruxolitinib | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ruxolitinib | DRUG | Ruxolitinib is a Janus kinase 1 (JAK1)/Janus kinase 2 (JAK2) inhibitor approved for clinical use in the treatment of splenomegaly, myelofibrosis, polycythaemia vera and graft-versus-host disease. It is an oral agent with a rapid mode of action. |
| Fostamatinib | DRUG | Fostamatinib is a tyrosine kinase inhibitor with activity against spleen tyrosine kinase (SYK). It has approved for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP). |
| Standard of care | OTHER | Standard of care treatment as per site-level policies and guidelines. |
Inclusion Criteria: * Patients age ≥ 18 years at screening * Patients with mild or moderate C19 pneumonia, defined as Grade 3 or 4 severity by the WHO COVID-19 Ordinal Scale by * Patients meeting criteria: Hospitalization AND SARS-CoV2 infection (clinically suspected\* or laboratory-confirmed) AND ...